Key facts
- It has raised $15.8M; the latest was Later Stage VC in Sep 2025.
- Notable investors include CAS Star, Lapam Capital, Zhongguancun Development Venture Capital Fund, Lotus Lake Ventures, Yuanhui Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Toll Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Toll Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Toll Biotech
Developer of biotechnology focusing on the research and development of new drugs for autoimmune diseases. The company has a number of small molecule patents that regulate innate immunity and has formed multiple pipelines in the research and development of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2020
- Website
- toll-biotech.com/
- Ownership
- Privately Held (backing)
Toll Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Toll Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Toll Biotech in its N-PORT filings yet. We sweep new filings monthly.